0.0000 (0.0000%)
  • Bid / Lots
    6.9000/ 1
  • Ask / Lots
    9.5000/ 4
  • Open / Previous Close
    0.0000 / 7.7500
  • Day Range
  • 52 Week Range
    Low 5.7500
    High 21.6800
  • Volume
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 7.92
09:32 ET32918.15
09:33 ET14158.21
09:39 ET5858.22
09:42 ET1008.16
09:53 ET16408.06
09:55 ET3008.08
10:04 ET7118.22
10:08 ET5008.31
10:18 ET2008.3
10:20 ET5008.1
10:26 ET2008.095
10:27 ET6008.04
10:29 ET2007.985
10:36 ET1007.95
10:44 ET1007.93
11:25 ET3008.13
11:32 ET2008.04
11:34 ET1008.05
11:36 ET8348.02
11:45 ET2008
11:50 ET2007.97
11:59 ET1007.94
12:06 ET5007.92
12:10 ET7507.8648
12:14 ET1007.76
12:15 ET2957.8685
12:19 ET1007.69
12:26 ET2007.835
12:28 ET4327.84
12:33 ET1008
12:44 ET1007.905
01:08 ET2007.96
01:24 ET3007.94
01:29 ET13197.88
01:33 ET8617.75
01:36 ET13007.79
01:38 ET1007.81
01:40 ET2297.77
01:42 ET5007.77
01:54 ET4007.69
01:56 ET1007.64
02:00 ET1007.68
02:03 ET1007.66
02:05 ET1007.65
02:12 ET5007.65
02:25 ET1007.66
02:30 ET1007.66
02:34 ET2007.66
02:39 ET2007.64
02:48 ET1007.65
02:52 ET6007.77
02:56 ET1007.7925
02:57 ET5007.73
03:08 ET9017.75
03:15 ET1007.68
03:17 ET1007.68
03:21 ET1007.64
03:24 ET3527.68
03:26 ET3007.7
03:32 ET1007.69
03:35 ET8507.69
03:42 ET5627.6854
03:53 ET1007.67
03:57 ET7217.71
04:00 ET59717.75
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesKNTE
Kinnate Biopharma Inc
United StatesOMGA
Omega Therapeutics Inc
United StatesCBAY
Cymabay Therapeutics Inc
United StatesOCGN
Ocugen Inc
United StatesPEPG
PepGen Inc
United StatesOABI
OmniAB Inc
As of 2022-12-02

Company Information

Kinnate Biopharma Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. Its products candidate include KIN-2787, KIN-3248 and KIN004. The KIN-2787 is a small molecule kinase inhibitor targeting specific classes of BRAF kinase alterations that characterize subsets of lung cancer, melanoma and other solid tumors. The Company has initiated a Phase I clinical trial for KIN-2787 (KN-8701). KIN-3248 is a small-molecule kinase inhibitor targeting cancer-associated alterations in FGFR2 and FGFR3 genes. KIN-3248 address the initial alteration and clinically-observed and predicted mutations in FGFR2 fusion gene-positive intrahepatic cholangiocarcinoma and FGFR3-altered ulcerative colitis. It is also developing a CDK12 inhibitor candidate to target the treatment of ovarian carcinoma, metastatic castration-resistant prostate cancer and triple-negative breast cancer.

Contact Information

11975 El Camino Real, Ste 101, Suite 101SAN DIEGO, CA, United States 92130


Independent Chairman of the Board
Dean Mitchell
President, Chief Executive Officer, Director
Nima Farzan
Chief Financial Officer, Executive Vice President - Corporate Development
Neha Krishnamohan
Chief Operating Officer, General Counsel
Mark Meltz
Chief Medical Officer
Richard Williams

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
Revenue (TTM)
Shares Outstanding
Dividend Yield
Annual Dividend Rate
Ex-Dividend Date
Pay Date
Book Value
P/E Ratio
Price/Sales (TTM)
Price/Cash Flow (TTM)
Operating Margin
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.